Business
Dermata Therapeutics Announces Participation at the H.C. Wainwright 26th Annual Global Investment Conference September 9-11, 2024
SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) ("Dermata" or the "Company"), a late-stage biotechnology
About this update from Dermata Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, CA / ACCESSWIRE / September 5, 2024 / Dermata Therapeutics, Inc. (Nasdaq:DRMA; DRMAW) (\"Dermata\" or the \"Company\"), a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions, today announced it will be presenting at the H.C. Wainwright 26th Annual Global Investment Conference, being held September 9-11, 2024.The in-person venue for the event is the Lotte New York Palace Hotel in New York City located at 455 Madison Avenue. Virtual participation will be staged simultaneously with over 550 company presentations scheduled as live feed or available on-demand.Gerry Proehl, Chairman, President, and Chief Executive Officer of Dermata, will provide an overview of the Company's business and an update on the Company's Phase 3 acne program during the presentation.If you are an investor, and would like to listen to the Company's presentation, please click on the following link (www.hcwevents.com/annualconference) to register for the conference.Over 550 corporate presentations and panels are available during September 9-11, 2024.Event: H.C. Wainwright 26th Annual Global Investment ConferenceDate: September 9-11, 2024Time: 7:00AM (Eastern Time)Location: Virtual to start on-demand on September 9 at 7:00 A.M. (ET)About Dermata TherapeuticsDermata Therapeutics, Inc. is a late-stage biotechnology company focusing on the treatment of medical and aesthetic skin diseases and conditions. The Company's lead product candidate, DMT310, is the Company's first product candidate being developed from its Spongilla technology platform and is currently being evaluated in a Phase 3 program. DMT310 is a once-weekly topical product candidate derived from a naturally sourced freshwater sponge with multiple unique mechanisms of action. DMT310 has been studied for the treatment of acne, rosacea, and psoriasis. The Company's second product candidate, DMT410, uses its Spongilla technology as a new method for topical intradermal delivery of botulinum toxin for the treatment of hyperhidrosis and multiple aesthetic skin conditions. Dermata is headquartered in San Diego, California. For more information, please visit http://www.dermatarx.com/.Forward-Looking StatementsStatements in this press release that are not strictly historical in nature are forward-looking statements. These statements are based...